Colestipol Hydrochloride
drugOn this page
Also known as ColestidColestid orangeColestipolColestipol hclColestid flavored colestidFlavored colestidNSC-147003
Summary
Colestipol Hydrochloride (CHEMBL1201474) is an approved unknown (ATC C10AC02); indicated across 8 conditions including cardiovascular disorder and myocardial ischemia.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Unknown
- ATC class: C10AC02
- Indications: 8 conditions
- Clinical trials: 6
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201474 |
| Name | Colestipol Hydrochloride |
| Type | Unknown |
| Max phase | 4 |
| ATC | C10AC02 |
Also known as: Colestid, Colestid orange, Colestipol, Colestipol hcl, Colestipol hydrochloride, Colestid flavored colestid, Flavored colestid, NSC-147003, COLESTIPOL HYDROCHLORIDE
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
8 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| cardiovascular disorder | 4 | MONDO:0004995 | EFO:0000319 |
| myocardial ischemia | 3 | MONDO:0024644 | EFO:1001375 |
| carotid artery disorder | 3 | MONDO:0005269 | EFO:0003781 |
| cerebral atherosclerosis | 3 | MONDO:0006694 | EFO:1000860 |
| coronary artery disorder | 3 | MONDO:0005010 | EFO:0001645 |
| breast neoplasm | 2 | MONDO:0021100 | MONDO:0007254 |
| erythropoietic protoporphyria | 2 | MONDO:0001676 | MONDO:0001676 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 6.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 2 |
| PHASE4 | 1 |
| PHASE2/PHASE3 | 1 |
| PHASE2 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00203476 | PHASE4 | COMPLETED | A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction |
| NCT00000512 | PHASE3 | COMPLETED | Familial Atherosclerosis Treatment Study |
| NCT00000599 | PHASE3 | COMPLETED | Cholesterol-Lowering Atherosclerosis Study (CLAS) |
| NCT01422915 | PHASE2/PHASE3 | COMPLETED | Sorbent Therapy of the Cutaneous Porphyrias |
| NCT02400476 | PHASE2 | COMPLETED | An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide |
| NCT02263547 | PHASE1 | TERMINATED | Rapid Elimination Procedure of Teriflunomide With Colestipol Hydrochloride |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).